Risk factors for progression to invasive carcinoma in patients with borderline ovarian tumors

2014 ◽  
Vol 133 ◽  
pp. 83
Author(s):  
T. Song ◽  
B.S. Yoon ◽  
Y.Y. Lee ◽  
C.H. Choi ◽  
T.J. Kim ◽  
...  
Keyword(s):  
Risk Factors ◽  
Invasive Carcinoma ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumors

Risk Factors for Progression to Invasive Carcinoma in Patients With Borderline Ovarian Tumors

2014 ◽  
Vol 24 (7) ◽  
pp. 1206-1214 ◽  
Author(s):  
Taejong Song ◽  
Yoo-Young Lee ◽  
Chel Hun Choi ◽  
Tae-Joong Kim ◽  
Jeong-Won Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Invasive Carcinoma ◽  
Advanced Disease ◽  
Recurrent Disease ◽  
Ovarian Tumors ◽  
Cox Proportional Hazards Model ◽  
Disease Stage ◽  
Borderline Ovarian Tumors ◽  
Advanced Disease Stage ◽  
Independent Risk Factors

ObjectiveThe aim of this study was to identify risk factors for progression to invasive carcinoma in patients with borderline ovarian tumors (BOTs).MethodsWe performed a retrospective review of all patients treated and followed for BOTs between 1996 and 2011. Multivariate Cox proportional hazards model analysis was performed to identify independent risk factors for progression to invasive carcinoma.ResultsA total of 364 patients were identified. During the median follow-up of 53.8 months, 31 patients (8.5%) developed recurrent disease: 12 (3.3%) had recurrent disease with progression to invasive carcinoma, and 19 (5.2%) had recurrent disease with borderline histology. Disease-related deaths (7/364; 1.7%) were observed only in patients with progression to invasive carcinoma. The multivariate analysis showed that independent risk factors for progression to invasive carcinoma were advanced disease stage (hazard ratio [HR], 5.59;P= 0.005), age 65 years or older (HR, 5.13;P= 0.037), and the presence of microinvasion (HR, 3.71;P= 0.047). These 3 factors were also independently related to overall survival.ConclusionsAlthough patients with BOTs have an excellent prognosis, the risk of progression to invasive carcinoma and thereby death remains. Therefore, physicians should pay closer attention to BOT patients with these risk factors (ie, advanced disease stage, old age, and microinvasion), and more careful surveillance for progression to invasive carcinoma is needed.

Risk Factors for Epithelial Borderline Ovarian Tumors: Results of a Swedish Case–Control Study

2001 ◽  
Vol 83 (3) ◽  
pp. 575-585 ◽  
Author(s):  
Tomas Riman ◽  
Paul W. Dickman ◽  
Staffan Nilsson ◽  
Nestor Correia ◽  
Hans Nordlinder ◽  
...  
Keyword(s):  
Risk Factors ◽  
Case Control Study ◽  
Case Control ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumors ◽  
Control Study

Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years

2018 ◽  
Vol 28 (9) ◽  
pp. 1643-1649 ◽  
Author(s):  
Li Sun ◽  
Ning Li ◽  
Yan Song ◽  
Guixiang Wang ◽  
Zitong Zhao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retrospective Study ◽  
Recurrence Rate ◽  
Conservative Surgery ◽  
Ovarian Tumors ◽  
Stage I ◽  
Clinicopathologic Features ◽  
Borderline Ovarian Tumors ◽  
Risk Factors For Recurrence

ObjectiveThis study aimed to evaluate the clinicopathologic features of mucinous borderline ovarian tumors (MBOTs), with an emphasis on the risk factors for recurrence.MethodsData of 76 patients with MBOT diagnosed and treated between 2000 and 2007 at a single institution were analyzed in this retrospective study. The clinicopathologic features of different tumor subgroups were analyzed, including pathology, surgical methodology, recurrence, and overall survival.ResultsThe median patient age was 40 years (13–85 years). Forty-six patients with gastrointestinal mucinous borderline tumors (intestinal MBOTs) (73.7%) and 20 patients with endocervical MBOT (26.3%) were identified. Forty radical surgeries and 26 conservative surgeries were performed. There were 74.6% patients (50/67) with stage I disease among the 67 patients who received comprehensive surgical staging.During a median follow-up time of 151 months, 9 recurrences were identified. Median duration from surgery to recurrence was 26.4 months (range, 13–50 months). There was no difference in recurrence rate between intestinal MBOT and endocervical MBOT (14.3% vs 5.0%; P > 0.05). The recurrence rate of stage III tumors was significantly higher than that of stage I (33.3% vs 8%; P < 0.05). The recurrence rate after conservative surgery was higher than that after radical procedures (21.4% vs 6.3%; P < 0.05).ConclusionsThe majority of patients with MBOT had a favorable prognosis. Patients with later-stage disease had a higher recurrence rate.

scholarly journals Risk factors for recurrence of borderline ovarian tumors in France: A multicenter retrospective study by the FRANCOGYN group

2020 ◽  
Author(s):  
Eva SANGNIER ◽  
Lobna OULDAMER ◽  
Sofiane BENDIFALLAH ◽  
Cyrille HUCHON ◽  
Pierre COLLINET ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retrospective Study ◽  
Ovarian Tumors ◽  
Borderline Ovarian Tumors ◽  
Risk Factors For Recurrence

Outcome of patients with borderline ovarian tumors: Results of the multicenter AGO ROBOT study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 5005-5005 ◽  
Author(s):  
Nikolaus De Gregorio ◽  
Klaus H. Baumann ◽  
Mignon-Denise Keyver-Paik ◽  
Alexander Reuss ◽  
Ulrich Canzler ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Disease Progression ◽  
Invasive Carcinoma ◽  
Residual Disease ◽  
Figo Stage ◽  
Ovarian Tumors ◽  
Surgical Staging ◽  
Data Set ◽  
Borderline Ovarian Tumors ◽  
Fertility Sparing

5005 Background: Borderline ovarian tumors (BOT) are a rare entity; current standard of care is based on the available data of predominantly small retrospective trials. Therefore we performed a pattern of care study including central pathology review. Methods: All consecutive patients diagnosed with BOT between 1998 and 2008 in 24 German institutions were included. Tumor samples were prospectively sent for central histopathological review to specialized gynecopathologists, clinical data were collected and patient follow-up was prospectively updated. Results: Pathological review was obtained in 1,042 of 1,236 pts resulting in 950 confirmed BOT cases analyzed here. Under- and overdiagnosis occurred in 3.8% and 5.0% of cases, respectively. Median age was 49 years; 84% of patients had FIGO stage I disease; serous type (S-BOT) was diagnosed in 64% and mucinous type (M-BOT) in 31%. Primary/re-staging surgery led to complete debulking in 92.3% of pts (residual disease 1.3%, unknown 6.4%). Adjuvant chemotherapy was given to 33 (3.5%) pts only. 165 (17%) underwent fertility preserving surgery and 31 (19%) of these patients had documented pregnancies thereafter. Overall, 74 (7.8%) pts experienced relapse and 43 (4.5%) died. Disease progression in the form of invasive carcinoma occurred in 30% of the relapses. Inadequate surgical staging, residual tumor, fertility sparing surgery and higher FIGO stage were associated with shorter progression-free survival (PFS). M-BOT showed a non-significant trend to longer PFS compared to S-BOT (p = 0.07). No differences were observed for laparatomy vs. laparoscopy as initial surgical approach or application of adjuvant chemotherapy. Conclusions: To this day, this is the largest data set available for BOT. Prognosis is favorable even without adjuvant therapy if correct surgical staging is performed. Both tumor characteristics and treatment variables had a significant impact on relapse rate and outcome. In contrast to previous studies, disease progression in the form of invasive carcinoma occurred in a significant amount of patients with relapsed disease.

Sign in / Sign up

Export Citation Format

Share Document